RALGPS2 and neoplasm: Silencing of BR serine/threonine-protein kinase 2 (BRSK2), Tankyrase (TNKS), Ral GEF with PH domain and SH3 binding motif 2 (RALGPS2), lysine demethylase 6A (KDM6A), and transducin β-like 1 X-linked (TBL1X) expression decreased the viability of tumor spheroids in response to cisplatin by approximately 30% compared to the cisplatin-treated siNC (Fig. 5C).